Emergent Biosolutions ((EBS)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Emergent BioSolutions is conducting an observational study titled ‘An Observational Clinical Study of AIGIV Use in Sporadic Cases of Systemic Anthrax.’ The study aims to assess the safety and clinical benefits of AIGIV (ANTHRASIL®) in treating patients with systemic anthrax. This research is significant as it seeks to gather data on the extent of anthrax illness, survival rates, and serum concentrations of AIGIV and anthrax toxins in affected patients.
Intervention/Treatment: The intervention being tested is AIGIV, a drug known as Anthrax Immune Globulin Intravenous (Human). It is intended to treat patients with systemic anthrax by following the licensed US prescribing information.
Study Design: The study is observational with a cohort model and a retrospective time perspective. This means it will look back at existing cases of systemic anthrax to evaluate the effects of AIGIV without manipulating the study environment or conditions.
Study Timeline: The study was first submitted on June 15, 2018, and the latest update was submitted on August 18, 2025. The study is not yet recruiting, indicating that patient enrollment has not started, but the timeline suggests ongoing preparations and updates.
Market Implications: This study update could influence Emergent BioSolutions’ stock performance and investor sentiment positively, as successful outcomes may enhance the company’s portfolio in biodefense. The involvement of prominent collaborators like the CDC and the Department of Health and Human Services underscores the study’s importance in the industry.
The study is ongoing, with further details available on the ClinicalTrials portal.